<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02589405</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.105041</org_study_id>
    <nct_id>NCT02589405</nct_id>
  </id_info>
  <brief_title>Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris</brief_title>
  <acronym>Benzac</acronym>
  <official_title>Benzaknen® 5% Gel in Combination With Dermotivin® Soft Liquid Soap and Non-comedogenic Cetaphil® Dermacontrol Moisturizer SPF30 in the Treatment of Mild-to-moderate Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Proinnovera GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate a complete acne regimen consisting of a medication
      (Benzaknen® 5% Gel), and 2 cosmetic products Dermotivin® Soft Liquid soap and Cetaphil®
      Dermacontrol Moisturizer SPF30 in patients with acne.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to evaluate subject satisfaction with the treatment
      regimen comprising Benzaknen® 5% Gel in association with 2 cosmetic products including a foam
      soap, Dermotivin® Soft Liquid soap, and a non comedogenic moisturizer, Cetaphil® Dermacontrol
      Moisturizer SPF30, in patients with mild to moderate acne, after 12 weeks of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject satisfaction questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Benzaknen treatment regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benzac® 5% Gel (once daily) + Dermotivin® Soft Liquid soap (twice daily) + Cetaphil® Dermacontrol Moisturizer SPF30 (once daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzoyl Peroxide</intervention_name>
    <arm_group_label>Benzaknen treatment regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dermotivin® Soft Liquid cleanser</intervention_name>
    <arm_group_label>Benzaknen treatment regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cetaphil® Dermacontrol Moisturizer SPF30</intervention_name>
    <arm_group_label>Benzaknen treatment regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject of any ethnic background of 12 years or older.

          -  Subject with mild or moderate facial acne vulgaris defined as an Investigator Global
             Assessment (IGA) score at 2 or 3 on a 0-4 scale.

          -  Subject with any skin phototype according to T.B. Fitzpatrick skin phototype
             definitions.

        Exclusion Criteria:

          -  Subject with severe acne (IGA&gt;3) with nodules, cysts, scars or extra-facial lesions,

          -  Female subject who is pregnant, lactating or planning a pregnancy during the study,

          -  Subject susceptible to take a corticosteroid treatment during the study except inhaled
             or topic when needed to treat a condition outside the face,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mi-Ran EGBERT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Proinnovera GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>EGBERT Mi-Ran</name>
      <address>
        <city>Münster</city>
        <zip>48159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 25, 2017</submitted>
    <returned>March 22, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

